Have any questions? 706-721-6582 or cts@augusta.edu
- A Phase 2, 12-week, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate Efficacy, Safety, Tolerability and Pharmacokinetics of 3Dose levels of TAK-831 in Adjunctive Treatment of Adult Subjects with Negative Symptoms of Schizophrenia
Clinical Trial
A Phase 2, 12-week, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate Efficacy, Safety, Tolerability and Pharmacokinetics of 3Dose levels of TAK-831 in Adjunctive Treatment of Adult Subjects with Negative Symptoms of Schizophrenia
The purpose of this study is to determine whether TAK-831 improves negative symptoms of schizophrenia, when taken together with an anti-psychotic medication. Negative symptoms include reduced expression of emotions, reduced feelings of pleasure in everyday life, difficulty beginning and sustaining activities, reduced socializing, and reduced speaking.
Eligibility Criteria
- Male or female patients age 18-60 years old Diagnosis of schizophrenia Must have an adult designated study partner who will help provide information about your symptoms and how they affect your activites.
RESEARCH. INNOVATION. DISCOVERY.